Rubius Therapeutics, a biotech engineering red blood cells as drug carriers, said today that it raised $120 million in an oversubscribed private financing round. The Cambridge, Mass.-based company plans to use its newly-acquired funds to support its Red-Cell Therapeutics portfolio and prepare for human clinical trials in 2018. “With this financing, Rubius is well positioned […]
